子宫内膜癌市场规模、份额和成长分析（按癌症类型、治疗方法、诊断方法、分期、最终用途和地区划分）—产业预测，2026-2033年

预计到 2024 年，全球子宫内膜癌市场规模将达到 301 亿美元，到 2025 年将成长至 315.7 亿美元，到 2033 年将成长至 463 亿美元，预测期（2026-2033 年）的复合年增长率为 4.9%。

由于发病率上升、公众意识提高以及医疗基础设施的完善，全球子宫内膜癌市场正经历强劲增长。诊断方法的创新，特别是分子谱分析和基因检测技术的进步，使得精准化和个人化治疗策略成为可能。标靶治疗、免疫疗法和联合疗法的出现，透过提高疗效并减少副作用，促进了市场扩张。此外，基因组分析和液态生物检体等技术的进步也为早期检测和个人化治疗方案提供了支持。然而，高昂的治疗费用、先进医疗设施的匮乏以及对有效早期检测技术的需求，仍然是亟待解决的关键挑战，以减轻全球子宫内膜癌的负担。

全球子宫内膜癌市场驱动因素

推动全球子宫内膜癌市场成长的关键因素是全球子宫内膜癌发生率的不断上升。作为最常见的妇科癌症之一，子宫内膜癌的发生率持续攀升，这主要是由于肥胖、荷尔蒙波动和糖尿病等风险因素的综合影响。病例数的激增凸显了对先进诊断和治疗方法的迫切需求，从而推动了市场的扩张。随着人们对子宫内膜癌的认识不断提高，以及对有效医疗解决方案需求的日益增长，预计该市场将迎来显着增长，这也反映了与疾病相关的持续挑战。

全球子宫内膜癌市场的阻碍因素

全球子宫内膜癌市场面临的主要挑战是治疗费用高昂和医疗资源匮乏，尤其是在发展中地区。手术、化疗和放射线治疗等治疗费用高昂，令许多患者难以负担，导致他们无法获得所需的治疗。对于那些医疗保险覆盖范围有限或经济资源不足的患者而言，情况更为严峻，造成治疗选择上的不平等，并阻碍了疾病的整体管理。确保人人都能公平地获得负担得起的医疗保健仍然是该市场面临的关键挑战。

全球子宫内膜癌市场趋势

目前，全球子宫内膜癌市场正经历动态变化，其特点是製药公司与研究机构之间开展了强而有力的合作和策略联盟。这种协同作用旨在加速药物研发，提高临床试验效率，这对于将创新疗法推向市场至关重要。因此，人们越来越重视改进诊断技术和引入新型疗法，以实现针对个别患者的个人化治疗。这些进展有望显着改善患者的治疗效果，推动子宫内膜癌领域对有效治疗方法的需求，最终改变癌症治疗模式。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球子宫内膜癌市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 子宫内膜癌
  • 腺癌
  • 癌症肉瘤
  • 鳞状细胞癌
  • 其他癌症类型
• 子宫肉瘤

全球子宫内膜癌市场规模（按治疗类型和复合年增长率划分）（2026-2033 年）

• 外科手术
• 化疗
• 放射线治疗
• 荷尔蒙疗法
• 标靶治疗
• 免疫疗法

全球子宫内膜癌市场规模（按诊断方法和复合年增长率划分）（2026-2033 年）

• 切片检查
• 骨盆腔超音波
• 子宫镜检查
• 电脑断层扫描
• 其他诊断方法

全球子宫内膜癌市场规模（依分期及复合年增长率划分）（2026-2033 年）

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

全球子宫内膜癌市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 医院
• 癌症中心
• 门诊手术中心

全球子宫内膜癌市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Notable Product：Keytruda（pembrolizumab）
• AstraZeneca plc（United Kingdom）
• Notable Product：Imfinzi（durvalumab）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol Myers Squibb Company（United States）
• Karyopharm Therapeutics Inc.（United States）
• Siemens Healthineers AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Incyte Corporation（United States）
• Context Therapeutics Inc.（United States）
• Evergreen Therapeutics, Inc.（United States）
• Sysmex Corporation（Japan）
• Gilead Sciences, Inc.（United States）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• Sanofi SA（France）

结论与建议

Global Endometrial Cancer Market size was valued at USD 30.1 Billion in 2024 and is poised to grow from USD 31.57 Billion in 2025 to USD 46.3 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The global endometrial cancer market is experiencing robust growth driven by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic methods, particularly molecular profiling and genetic testing, facilitate accurate and personalized treatment strategies. The emergence of targeted therapies, immunotherapies, and combination treatment approaches contributes to market expansion by improving efficacy and minimizing adverse effects compared to conventional treatments. Furthermore, advancements like genomic profiling and liquid biopsies support early detection efforts and customized therapy options. Nevertheless, obstacles such as high treatment costs, limited access to advanced healthcare facilities, and the necessity for effective early detection techniques pose significant challenges that must be addressed to alleviate the global endometrial cancer burden.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segments Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

A significant factor propelling the global endometrial cancer market is the rising incidence of endometrial cancer across the globe. As one of the most prevalent gynecological cancers, its occurrence is on the upswing, largely due to a combination of risk factors like obesity, hormonal fluctuations, and diabetes. This surge in cases highlights the urgent need for advanced diagnostic and treatment options, boosting the market's expansion. As awareness regarding endometrial cancer grows and the demand for effective healthcare solutions increases, the market is poised for substantial growth, reflecting the ongoing challenges associated with this disease.

Restraints in the Global Endometrial Cancer Market

A notable challenge facing the global endometrial cancer market is the significant expense associated with treatment and the lack of accessibility to healthcare services, particularly in underdeveloped areas. The financial burden of treatments, such as surgeries, chemotherapy, and radiation therapy, can be quite high, preventing many patients from receiving the necessary care. This situation is exacerbated for individuals with limited health insurance coverage or insufficient financial resources, leading to disparities in treatment options and hindering the overall management of the disease. Ensuring equitable access to affordable care remains a critical issue within the market.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is currently experiencing a dynamic shift characterized by robust collaborations and strategic partnerships between pharmaceutical companies and research institutions. This synergy is focused on expediting drug development and enhancing clinical trial efficiency, which is critical for bringing innovative treatments to market. As a result, there is a growing emphasis on improved diagnostics and the introduction of novel therapies designed to tailor treatment to individual patient needs. These advancements are anticipated to significantly enhance patient outcomes, driving demand for effective solutions in the endometrial cancer space and ultimately transforming the landscape of cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2026-2033)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations